Trustworthy transplant research—now easier to find.
Explore Study Summaries organized by disease and condition: lymphoma, multiple myeloma, sickle cell disease, and more.
Start exploring ➡️cibmtr.org/summaries
Our study summaries page just got a major upgrade!
Search by category, find what you need faster, and browse clear, plain‑language summaries.
Explore the new layout ➡️ cibmtr.org/summaries
Today at #EBMT26: Hear about outcomes from the NMDP-sponsored ACCESS trial:
Live at #EBMT26 today: CIBMTR oral and poster abstracts! Take a look:
📢 Now Hiring: Program Director I – Statistical Operations (CIBMTR)
Lead biostatistics teams and collaborate with medical & scientific researchers across the full research lifecycle, advancing high‑impact BMT research.
🔗 Apply: mcw.wd503.myworkdayjobs.com/ExternalCare...
#Hiring #Biostatistics
Attending #EBMT26? Make sure to check out these abstracts today. Don’t miss these oral and poster abstracts!
#EBMT26 begins today! Here’s the full schedule of CIBMTR abstracts being presented this week.
Coming soon to #EBMT26: CIBMTR will present a variety of oral and poster abstracts. Here’s a quick overview of when this research will be featured throughout the meeting.
New tool predicts acute graft-vs-host disease after transplant. Read about this CIBMTR study to learn more:cibmtr.org/Patient-Summ...
CHARM predicts who may need extra care after transplant. Read about this CIBMTR study to learn more: cibmtr.org/Patient-Summ...
People with sickle cell trait can safely donate bone marrow. Read about this CIBMTR study to learn more: cibmtr.org/Patient-Summ...
Graphs can help patients and doctors see healing over time. Read about this CIBMTR study to learn more: cibmtr.org/Patient-Summ...
Some children with SCID might not need chemotherapy before transplant or GVHD medicines after transplant. Read about this CIBMTR study to learn more: cibmtr.org/Patient-Summ...
Don't miss this! Abstracts from #Tandem26 are now available to view online. Explore the full collection here: www.astctjournal.org/issue/S2666-...
A special congratulations to Dr. Stella Davies, our #Tandem26 Mortimer M. Bortin lecturer! It is our pleasure to now hear, “Waiting until Evening to See How Splendid the Day Has Been: Aging and Transplant at the Extremes of the Lifespan” this evening!
Dr. Rachel Cusatis, CIBMTR Senior Scientific Director, is now presenting oral abstract, “Mismatch Doesn’t Mean Misfortune: Quality of Life after HCT in the ACCESS Trial,” at #Tandem26.
Have you had a chance to visit the #Tandem26 exhibit hall? Make sure to stop by the Tandem Meetings Hub to visit with CIBMTR staff! Open today until 3 p.m. and 9 a.m.-12 p.m. tomorrow!
Session recap banner - Plenary: Access/Logistical Challenges And Development of Novel Therapies
A Wednesday session at #Tandem26 took a closer look at where gene therapy stands today—what’s working, what’s holding it back, and what’s coming next. Check out the full recap in Tandem Meeting News: www.tandemmeetingsnews.com/experts-disc...
What's next for HCT and cellular therapies? The #Tandem26 opening-day plenary examined progress from breakthrough to bedside — looking toward equitable access and improved care. Read more in Tandem Meeting News: www.tandemmeetingsnews.com/joint-plenar...
#tandem26 #bmtsm Spellman: @cibmtr.bsky.social study shows equivalent GRFS w MRD and MUD but alternative donors far slightly worse. Avoid DPB1np mm in MUD, but this mm type *may* be protective in haplo.
#tandem26 #bmtsm Spellman: matched sibs remain preferred donor when available, though some are starting to use age cap ~40-50, though this remains uncertain.
#tandem26 #bmtsm Spellman: updated guidelines for donor selection from @cibmtr.bsky.social. Partially driven by massive expanded use of PTCy.
#tandem26 #bmtsm Auletta: world-wide unrelated and haplodentical donors are driving growth in alloHCT. PTCy has rapidly become predominant GVHD ppx across donor types.
🔬 NMDP and CIBMTR are presenting new findings from the ACCESS study at #Tandem2026.
These new findings highlight important dimensions of transplant outcomes and patient experience following mismatched unrelated donor (MMUD) transplantation 👉 go.nmdp.org/Tandem2026
Attending #Tandem26 and looking for session locations in the Salt Palace Convention Center? Here are few helpful maps! @astct.bsky.social
Dr. Miguel-Angel Perales (@drmiguelperales.bsky.social) concludes the CIBMTR Concurrent Session with “Use of CIBMTR One Year Survival Calculator for Retrospective Analysis” at #Tandem26 this morning!
Drs. Doug Rizzo and Navneet Majhail (@bldcancerdoc.bsky.social) collaborate to chair the outstanding “Concurrent: Beyond the Report Card – Advancing Research and Quality through Center Specific Outcomes Reporting [CIBMTR]” this morning at #Tandem26
It's not too late to add the NMDP/CIBMTR community to your #Tandem2026 agenda! Check out these notable presentations from the ACCESS Trial ⬇️
